CTRI/2011/12/002266尚未招募未知
A multicentre, randomized, open-label, single dose, two-treatment, three-period, three sequence, partial replicate, crossover, pivotal bioequivalence study of Test capecitabine 500 mg tablets manufactured by Reliance Life Sciences Pvt. Ltd., India with Xeloda® (capecitabine 500 mg) manufactured by Roche Pharma AG, Germany in adult, human, cancer patients under fed condition.
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Males or females 18 to 70 years of age.
- •Patients with Body Mass Index (BMI) between 17 kg/m2 and 30 kg/m2.
- •Patients with histopathologically/ cytologically confirmed breast cancer or colorectal cancer.
- •Cancer patients who are already receiving stable twice daily dosing regimen of capecitabine as prescribed by treating physician.
- •Patients with Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
- •Patients with life expectancy of at least 3 months.
- •Patients should be non-smokers.
- •Patients willing to voluntarily provide written informed consent or consent from a Legally Acceptable Representative (LAR), if the patient is not in a condition to give consent.
排除标准
- •Patients with inadequate venous access to allow the collection of all samples via venous cannula in the study.
- •Pregnant (female patients with a positive urine pregnancy test at screening and positive serum pregnancy test before period I of hospitalization) or lactating females.
- •Patients with the following abnormal laboratory parameters:
- •a.Serum creatinine more than 2.0 times of upper normal limit
- •b.Aspartate amino transferase (AST) or alanine amino transferase (ALT) more than 2.5 times of upper normal limit
- •c.Alkaline phosphatase >= 1.5 times of upper normal limit
- •d.Platelet count les than 100,000/μL.
- •e.Hemoglobin less than 8.0 g/dL.
- •f.Absolute Neutrophil Count (ANC) less than 1.5 x 10 to power 9 /L.
- •Patients with a known hypersensitivity to fluoropyrimidine therapy or known sensitivity to 5- fluorouracil or known Dihydropyrimidine dehydrogenase (DPD) deficiency.
- •Patients with known brain metastasis and/or pre-existing motor or sensory neurotoxicity of severity >=2 by National; Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) criteria.
- •History or evidence of uncontrolled coagulopathy.
- •History of hereditary galactose/ glucose/ lactase disorders.
- •History or evidence of cardiac disease (Myocardial Infarction in last 6 months, unstable angina, heart failure, uncontrolled ventricular arrhythmia, significant pericardial disease).
- •Patients with a history of alcoholism, found with current alcohol abuse based on Alcohol breath test and/ or drug abuse or who test positive in the urinary screening for drugs of abuse (Amphetamines, Morphine, Benzodiazepines, Marijuana, Cocaine and Barbiturates) except as required as medication for the current medical condition.
- •Patients diagnosed to be HIV 1 and 2 or Hepatitis B (HBsAg) or Hepatitis C (HCV) virus positive.
- •Patients having an abnormal serum calcium level at screening visit which as judged by the investigator could lead to safety risk to the patient upon participation in the trial or could interfere with the conduct of the trial.
- •Patients who have participated in any other clinical investigation using experimental drugs or have bled more than 300 mL in the past 3 months.
- •Any other condition which the investigator feels would pose a significant hazard to the patient if IP is administered.
研究者
相似试验
进行中（未招募）
不适用
To study the effect of two drugs â?? Capecitabine 500 mg (Test product by Reliance Life Sciences Pvt. Ltd., India) and Xeloda® (Capecitabine 500 mg by Roche Pharma AG, Germany)CTRI/2014/10/005130Reliance Life Sciences Pvt Ltd
招募中
不适用
Clinical trial to compare two drugs, Temodal and Temozolomide 250 mg capsules in cancer patientsCTRI/2011/12/002274Reliance Life Sciences Pvt Ltd24
已完成
不适用
Comparison of two Imatinib Mesylate tablets in patients of Philadelphia chromosome positive Chronic Myeloid Leukaemia stabilized on Imatinib Mesylate tablets 400mgCTRI/2013/07/003836Ranbaxy Laboratories Limited42
尚未招募
不适用
A Bioequivalence Study of Ferric Carboxymaltose Intravenous Injection in Adult Patients with Iron Deficiency AnaemiaCTRI/2021/08/036072Dr Reddys Laboratories Ltd
已完成
不适用
The is a study which is Multicentric, Parallel Arm Bioequivalence Study of Ferric Carboxymaltose Intravenous Injection (750 mg Iron/15 mL) of Dr. Reddy’s Laboratories Ltd, India, with that of Injectafer® of American Regent Inc USA Under Fasting Condition in Adult Patients.CTRI/2023/08/056038Dr. Reddy’s Laboratories Limited120